The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Part of paid clinical trials in New York, New York.

Sponsor
Medical College of Wisconsin
Study ID
NCT03694262
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rucaparib — DRUG
    Rucaparib 600mg orally twice daily by continuous dosing
  • Bevacizumab — DRUG
    15mg/kg IV on day 1 of every cycle
  • Atezolizumab — DRUG
    1,200mg IV on day 1 of every cycle

Study Details

To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.

Key Dates

Start date
Jul 19, 2019
Status verified
Mar 2026
Primary completion
Mar 30, 2023
Completion
Mar 10, 2026

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Cycle length = 21 days Atezolizumab 1,200mg IV on day 1 Bevacizumab 15mg/kg IV on day 1 Rucaparib 600mg orally twice daily by continuous dosing

Primary Outcome Measure

Treatment Related Overall Response Rate [ Time Frame: 44 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Mount SinaiNew YorkNew York10029-
St. Luke's Hospital and Health NetworkBethlehemPennsylvania18015-
Froedtert Lutheran Memorial HospitalMilwaukeeWisconsin53226-

Related coverage on Hipa.ai

Find similar trials in New York, NY

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Mount Sinai· New York, NYSt. Luke's Hospital and Health Network· Bethlehem, PAFroedtert Lutheran Memorial Hospital· Milwaukee, WI

Related Studies